Cargando…
Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy
BACKGROUND: travellers’ diarrhoea (TD) is frequently reported with incidence up to 40% in high-risk destinations. Previous studies showed that the number of loose stools alone is inadequate to holistically predict the severity of TD. To improve the prediction of prognosis and to optimize treatments,...
Autores principales: | DuPont, Herbert L, Almenoff, June S, Jamindar, Mansi S, Bortey, Enoch, Steffen, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628770/ https://www.ncbi.nlm.nih.gov/pubmed/37052453 http://dx.doi.org/10.1093/jtm/taad043 |
Ejemplares similares
-
Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers’ diarrhoea: reply
por: Steffen, Robert, et al.
Publicado: (2019) -
Rifamycin SV-MMX(®) for treatment of travellers’ diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria
por: Steffen, Robert, et al.
Publicado: (2018) -
Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies
por: Chey, William D, et al.
Publicado: (2023) -
Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX(®) Modified Release Tablets in Healthy Male and Female Volunteers
por: Di Stefano, Andrea Francesco Daniele, et al.
Publicado: (2021) -
The Ansamycin Antibiotic, Rifamycin SV, Inhibits BCL6 Transcriptional Repression and Forms a Complex with the BCL6-BTB/POZ Domain
por: Evans, Sian E., et al.
Publicado: (2014)